Successful treatment of linear immunoglobulin A bullous dermatosis with dupilumab in a pediatric patient

Almuhanna, Nouf; Alhamazani, Rasha; Alkhezzi, Sarah; Alfataih, Mahdi Turki Bin Ali; Almalki, Salman; Alrashidi, Anwar R.; Alhomida, Faris A.

doi:10.1016/j.jdcr.2023.05.040

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, case reports have described dupilumab's effectiveness in children. 13 Other biologics, including omalizumab and ustekinumab, have been successfully used to treat LABD. 14,15…”

Section: Discussionmentioning

confidence: 99%

Adult‐onset linear IgA bullous dermatosis: a retrospective single‐center cohort study of 81 patients and literature review

Wang,

Lehman,

Todd

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundLinear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disorder that may be drug‐induced or paraneoplastic. We aim to characterize features of LABD and determine differentiating factors among idiopathic, drug‐induced, or malignancy‐associated diseases.MethodsWe conducted a single‐center retrospective chart review of adult patients with linear IgA bullous dermatosis at a large tertiary referral center and a literature review of adult linear IgA bullous dermatosis.ResultsEighty‐one patients were included in the study. Ten patients (12.3%) had comorbid malignancy and nine (11.1%) had inflammatory bowel disease. Median disease duration was significantly shorter in both drug‐induced (1.2 vs. 48.8 months; P < 0.001) and malignancy‐associated (1.7 vs. 48.8 months; P < 0.001) LABD compared with idiopathic LABD. Recurrent episodes occurred significantly more often in idiopathic LABD compared to those with drug‐induced (76.1 vs. 11.5%; P < 0.001) or malignancy‐associated disease (76.1 vs. 33.3%; P = 0.019). Time to diagnosis was significantly shorter in the drug‐induced (0.2 vs. 5.4 months; P < 0.001) and malignancy‐associated groups (0.7 vs. 5.4 months; P = 0.049) compared with idiopathic; similarly, time to improvement was significantly shorter in both drug‐induced (0.4 vs. 3.0 months; P < 0.001) and malignancy‐associated disease (1.1 vs. 3.0 months; P = 0.016). Clinical morphology was indistinguishable between groups. Limitations included retrospective data collection, data from tertiary referral centers, and limited racial and ethnic diversity.ConclusionScreening for underlying malignancy, as well as for a predisposing medication or possibly inflammatory bowel disease, may be advisable in patients with LABD, particularly when it is newly diagnosed.

show abstract

“…So far, case reports have described dupilumab's effectiveness in children. 13 Other biologics, including omalizumab and ustekinumab, have been successfully used to treat LABD. 14,15…”

Section: Discussionmentioning

confidence: 99%

Adult‐onset linear IgA bullous dermatosis: a retrospective single‐center cohort study of 81 patients and literature review

Wang,

Lehman,

Todd

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“… 2 However, dapsone may induce hemolytic anemia and is thus avoided in patients with risk factors, including G6PD deficiency. In the case presented by Almuhanna et al, 1 the patient had anemia, which precluded the use of dapsone. Similarly, our patient had a low G6PD level, which put him at a high risk of hemolytic anemia.…”

mentioning

confidence: 93%

“…To the Editor: In the recently published article “Successful treatment of linear immunoglobulin A bullous dermatosis with dupilumab in a pediatric patient,” Almuhanna et al 1 described the first reported case to date of linear IgA bullous dermatosis (LABD) successfully treated with dupilumab in a 7-year-old patient.…”

mentioning

confidence: 99%

Letter in reply: Linear IgA bullous dermatosis treated with dupilumab in a pediatric patient with glucose-6-phosphate dehydrogenase deficiency

Muzumdar,

Bibb,

Sloan

et al. 2024

JAAD Case Reports

View full text Add to dashboard Cite

“…To the Editor: We read with interest the report by Almuhanna et al 1 on the remarkable response to the off-label use of dupilumab in a 7-year-old boy with linear IgA bullous dermatosis. This case report highlights the challenges of treating linear IgA bullous dermatosis with the current conventional treatment.…”

mentioning

confidence: 99%

Treatment of chronic bullous disease of childhood with dupilumab after dapsone-induced methemoglobinemia in a 2-year-old female patient

Yousefian,

Deligonul,

Swanson

2023

JAAD Case Reports

View full text Add to dashboard Cite

Successful treatment of linear immunoglobulin A bullous dermatosis with dupilumab in a pediatric patient

Cited by 5 publications

References 6 publications

Adult‐onset linear IgA bullous dermatosis: a retrospective single‐center cohort study of 81 patients and literature review

Adult‐onset linear IgA bullous dermatosis: a retrospective single‐center cohort study of 81 patients and literature review

Letter in reply: Linear IgA bullous dermatosis treated with dupilumab in a pediatric patient with glucose-6-phosphate dehydrogenase deficiency

Treatment of chronic bullous disease of childhood with dupilumab after dapsone-induced methemoglobinemia in a 2-year-old female patient

Contact Info

Product

Resources

About